On another note, there is some thought that tamoxifen should be D/C'd for hospitalized individuals with COVID. Both the med and COVID increase blood clot risk. In Europe, Groupe d'intérêt en Hémostase Périopératoire (GIHP) and the Groupe Français d'études sur l’Hémostase et la Thrombose (GFHT) is recommend to discontinue Tamoxifen in hospitalized patients with COVID 19 for thrombosis prevention and in patients who require thromboprophylaxis. I don't know of any US guidance on the subject, but provocative thought.